Turning adversity into opportunity: Small extracellular vesicles as nanocarriers for tumor-associated macrophages re-education.
TAMs re‐education
cancer
immunotherapy
macrophages
nanocarrier engineering
small extracellular vesicles
Journal
Bioengineering & translational medicine
ISSN: 2380-6761
Titre abrégé: Bioeng Transl Med
Pays: United States
ID NLM: 101689146
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
received:
28
02
2022
revised:
18
04
2022
accepted:
21
04
2022
entrez:
23
1
2023
pubmed:
24
1
2023
medline:
24
1
2023
Statut:
epublish
Résumé
Currently, small extracellular vesicles (sEV) as a nanoscale drug delivery system, are undergoing biotechnological scaling and clinical validation. Nonetheless, preclinical pharmacokinetic studies revealed that sEV are predominantly uptaken by macrophages. Although this "sEV-macrophage" propensity represents a disadvantage in terms of sEV targeting and their bioavailability as nanocarriers, it also represents a strategic advantage for those therapies that involve macrophages. Such is the case of tumor-associated macrophages (TAMs), which can reprogram/repolarize their predominantly immunosuppressive and tumor-supportive phenotype toward an immunostimulatory and anti-tumor phenotype using sEV as nanocarriers of TAMs reprogramming molecules. In this design, sEV represents an advantageous delivery system, providing precision to the therapy by simultaneously matching their tropism to the therapeutic cell target. Here, we review the current knowledge of the role of TAMs in the tumoral microenvironment and the effect generated by the reprogramming of these phagocytic cells fate using sEV. Finally, we discuss how these vesicles can be engineered by different bioengineering techniques to improve their therapeutic cargo loading and preferential uptake by TAMs.
Identifiants
pubmed: 36684102
doi: 10.1002/btm2.10349
pii: BTM210349
pmc: PMC9842057
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e10349Informations de copyright
© 2022 The Authors. Bioengineering & Translational Medicine published by Wiley Periodicals LLC on behalf of American Institute of Chemical Engineers.
Déclaration de conflit d'intérêts
Francisca Alcayaga‐Miranda received stipends from Cells for Cells. The other authors have no conflicts of interest to declare.
Références
Science. 2014 May 23;344(6186):921-5
pubmed: 24812208
Immunity. 2016 Mar 15;44(3):439-449
pubmed: 26982352
J Biotechnol. 2013 May 20;165(2):77-84
pubmed: 23562828
Br J Cancer. 2019 Jan;120(1):45-53
pubmed: 30413828
J Biomed Sci. 2019 Oct 20;26(1):78
pubmed: 31629410
Immunotherapy. 2019 Jun;11(8):677-689
pubmed: 31088236
Int J Mol Sci. 2018 Nov 30;19(12):
pubmed: 30513582
Biomaterials. 2021 Jan;268:120546
pubmed: 33253966
Oncotarget. 2017 May 2;8(18):30576-30586
pubmed: 28427165
Nutrients. 2019 Sep 20;11(10):
pubmed: 31547048
Immunol Rev. 2017 Mar;276(1):52-65
pubmed: 28258699
Oncotarget. 2016 Jun 28;7(26):40451-40460
pubmed: 27248173
Cancer Immunol Immunother. 2021 May;70(5):1323-1339
pubmed: 33140190
EBioMedicine. 2019 May;43:67-81
pubmed: 30956175
Nanoscale. 2020 Nov 12;12(43):22268-22280
pubmed: 33146206
Bioconjug Chem. 2014 Oct 15;25(10):1777-84
pubmed: 25220352
J Extracell Vesicles. 2015 Feb 09;4:26238
pubmed: 25669322
J Extracell Vesicles. 2017 Jun 14;6(1):1333882
pubmed: 28717424
Biomaterials. 2018 Sep;178:302-316
pubmed: 29982104
Biomaterials. 2021 Jan;268:120601
pubmed: 33338932
Annu Rev Pathol. 2020 Jan 24;15:123-147
pubmed: 31530089
Biomaterials. 2017 Oct;142:1-12
pubmed: 28715655
Blood. 2014 Jan 9;123(2):208-16
pubmed: 24255917
Carcinogenesis. 2018 Dec 13;39(11):1368-1379
pubmed: 30184100
J Extracell Vesicles. 2021 Feb;10(4):e12057
pubmed: 33643546
Cancers (Basel). 2021 Apr 13;13(8):
pubmed: 33924378
J Control Release. 2015 Jun 10;207:18-30
pubmed: 25836593
Biomaterials. 2020 Feb;230:119606
pubmed: 31806405
JCI Insight. 2019 Apr 16;5:
pubmed: 30990466
Sci Rep. 2019 Jan 24;9(1):663
pubmed: 30679544
Eur J Pharm Biopharm. 2016 Jan;98:1-8
pubmed: 26545617
Int Immunopharmacol. 2021 Oct;99:107960
pubmed: 34284286
Ann Surg Oncol. 2020 Feb;27(2):599-607
pubmed: 31407173
J Extracell Vesicles. 2015 Apr 20;4:26316
pubmed: 25899407
Front Immunol. 2020 Dec 03;11:583084
pubmed: 33365025
Sci Rep. 2016 Feb 25;6:21933
pubmed: 26911358
Nanoscale. 2020 Jan 7;12(1):130-144
pubmed: 31799577
Nat Rev Drug Discov. 2018 Dec;17(12):887-904
pubmed: 30361552
Nat Commun. 2018 Apr 3;9(1):1305
pubmed: 29610454
Hum Pathol. 2015 Mar;46(3):357-65
pubmed: 25540867
Cancer Res. 2009 Oct 15;69(20):8067-75
pubmed: 19826049
Biomaterials. 2016 Oct;105:195-205
pubmed: 27522254
Cancer Cell. 2015 Apr 13;27(4):462-72
pubmed: 25858805
Nat Rev Clin Oncol. 2017 Jul;14(7):399-416
pubmed: 28117416
Nat Commun. 2020 Feb 28;11(1):1064
pubmed: 32111836
Eur J Pharm Sci. 2017 Jan 1;96:316-322
pubmed: 27720897
Front Oncol. 2019 Sep 11;9:883
pubmed: 31572677
Nanoscale. 2020 Aug 20;12(32):16851-16863
pubmed: 32761008
Nat Biotechnol. 2011 Apr;29(4):341-5
pubmed: 21423189
Leukemia. 2014 Apr;28(4):970-3
pubmed: 24445866
Life Sci. 2021 Oct 1;282:119800
pubmed: 34245773
Biomaterials. 2018 Nov;183:280-294
pubmed: 30179778
Blood. 2010 Jan 21;115(3):696-705
pubmed: 19903899
Theranostics. 2020 May 15;10(14):6122-6135
pubmed: 32483443
Cancer Cell. 2013 Mar 18;23(3):277-86
pubmed: 23518347
BioDrugs. 2020 Oct;34(5):567-586
pubmed: 32754790
Nature. 2017 Jun 22;546(7659):498-503
pubmed: 28607485
Cancer Cell. 2017 Dec 11;32(6):869-883.e5
pubmed: 29232557
Front Oncol. 2021 May 17;11:679928
pubmed: 34079767
Sci Rep. 2018 Jul 3;8(1):9987
pubmed: 29968812
Oncoimmunology. 2018 Dec 12;8(3):1548241
pubmed: 30723576
Clin Cancer Res. 2020 Feb 15;26(4):970-977
pubmed: 31615933
Cell. 2017 May 4;169(4):736-749.e18
pubmed: 28475899
Nat Immunol. 2012 Nov;13(11):1118-28
pubmed: 23023392
Nat Biomed Eng. 2020 Jan;4(1):69-83
pubmed: 31844155
Trends Immunol. 2004 Dec;25(12):677-86
pubmed: 15530839
Gynecol Oncol. 2017 Mar;144(3):607-612
pubmed: 28065619
Nat Med. 2013 Oct;19(10):1264-72
pubmed: 24056773
Int J Nanomedicine. 2018 Nov 20;13:7727-7747
pubmed: 30538455
J Neurooncol. 2020 Feb;146(3):417-426
pubmed: 32020472
Nature. 2016 Nov 17;539(7629):437-442
pubmed: 27642729
Biomater Sci. 2020 Dec 15;8(24):7166-7176
pubmed: 33169732
Semin Cancer Biol. 2013 Dec;23(6 Pt B):522-32
pubmed: 24012661
Carbohydr Polym. 2020 Dec 15;250:116904
pubmed: 33049880
J Extracell Vesicles. 2021 Jun;10(8):e12085
pubmed: 34194679
Science. 2020 Feb 7;367(6478):
pubmed: 32029601
Int J Colorectal Dis. 2020 Jul;35(7):1203-1210
pubmed: 32303831
Immunology. 2007 Jan;120(1):90-102
pubmed: 17073943
Mol Ther. 2018 Feb 7;26(2):568-581
pubmed: 29292163
Theranostics. 2019 Jan 30;9(4):1015-1028
pubmed: 30867813
Cancer Manag Res. 2019 May 03;11:4041-4058
pubmed: 31118813
Nanomedicine. 2018 Jan;14(1):195-204
pubmed: 28982587
Cell. 2017 May 4;169(4):750-765.e17
pubmed: 28475900
NPJ Breast Cancer. 2016;2:
pubmed: 26998515
J Extracell Biol. 2022 Oct;1(10):
pubmed: 36591537
Nat Med. 2017 May;23(5):551-555
pubmed: 28346412
J Control Release. 2016 Feb 28;224:103-111
pubmed: 26772876
J Allergy Clin Immunol. 2019 Apr;143(4):1536-1548
pubmed: 30445062
Biomacromolecules. 2019 Jul 8;20(7):2873-2887
pubmed: 31185162
Front Immunol. 2020 Feb 28;11:89
pubmed: 32184777
J Control Release. 2015 Dec 28;220(Pt B):727-37
pubmed: 26390807
Nat Cell Biol. 2007 Jun;9(6):654-9
pubmed: 17486113
Nanomedicine. 2016 Apr;12(3):655-664
pubmed: 26586551
Biomater Sci. 2019 Nov 19;7(12):5027-5034
pubmed: 31528908
Mol Ther. 2019 Dec 4;27(12):2111-2122
pubmed: 31501034
Int J Nanomedicine. 2015 Oct 01;10:6185-97
pubmed: 26491291
Sci Transl Med. 2020 Sep 16;12(561):
pubmed: 32938792
Stem Cell Res Ther. 2020 Jul 10;11(1):276
pubmed: 32650828
Methods Mol Biol. 2016;1448:249-60
pubmed: 27317186
Nat Commun. 2016 Jul 22;7:12277
pubmed: 27447450
Nat Commun. 2021 Jan 19;12(1):440
pubmed: 33469052
Sci Transl Med. 2013 Oct 16;5(207):207ra144
pubmed: 24132639
Processes (Basel). 2021 Feb;9(2):
pubmed: 33954091
Cancer Lett. 2019 Oct 1;461:1-9
pubmed: 31288064
Immunity. 2014 Feb 20;40(2):274-88
pubmed: 24530056
Int J Mol Sci. 2021 Sep 02;22(17):
pubmed: 34502452
Chem Sci. 2018 Jan 31;9(10):2674-2689
pubmed: 29732051
Cancer Cell. 2019 Apr 15;35(4):588-602.e10
pubmed: 30930117
Acta Biomater. 2021 Oct 1;133:231-243
pubmed: 33011297
ACS Nano. 2014 Jan 28;8(1):483-494
pubmed: 24383518
J Hematol Oncol. 2019 Jul 12;12(1):76
pubmed: 31300030
J Hematol Oncol. 2015 Oct 29;8:122
pubmed: 26514126
J Immunol. 2000 Jun 15;164(12):6166-73
pubmed: 10843666
Nat Rev Cancer. 2013 Nov;13(11):759-71
pubmed: 24154716
J Neuroimmune Pharmacol. 2020 Sep;15(3):487-500
pubmed: 31722094
Biomaterials. 2014 Feb;35(7):2383-90
pubmed: 24345736
Bioeng Transl Med. 2022 Jun 09;8(1):e10349
pubmed: 36684102
Nat Commun. 2019 Sep 3;10(1):3974
pubmed: 31481662
Eur J Immunol. 2019 May;49(5):801-811
pubmed: 30779113
Arch Immunol Ther Exp (Warsz). 2020 Oct 23;68(6):33
pubmed: 33095374
Biomaterials. 2016 Jun;90:72-84
pubmed: 26994345
Nat Nanotechnol. 2018 Jan;13(1):82-89
pubmed: 29230043
J Adv Res. 2021 Jan 08;31:61-74
pubmed: 34194832
Dis Model Mech. 2017 Mar 1;10(3):259-270
pubmed: 28250051
J Control Release. 2015 May 10;205:35-44
pubmed: 25483424
Cancer Res. 2018 Aug 15;78(16):4586-4598
pubmed: 29880482
Mol Ther. 2017 Jun 7;25(6):1269-1278
pubmed: 28412169
J Clin Invest. 2012 Mar;122(3):787-95
pubmed: 22378047
Curr Drug Metab. 2011 May;12(4):313-28
pubmed: 21395530
J Immunother Cancer. 2020 Sep;8(2):
pubmed: 32948650
Int J Nanomedicine. 2017 Apr 18;12:3153-3170
pubmed: 28458537
J Nanobiotechnology. 2020 Jan 9;18(1):10
pubmed: 31918721
Cancer Metastasis Rev. 2006 Sep;25(3):315-22
pubmed: 16967326
Cell Metab. 2019 Jul 2;30(1):36-50
pubmed: 31269428
BMC Med. 2016 Oct 17;14(1):159
pubmed: 27745550
Int J Nanomedicine. 2019 May 02;14:3203-3220
pubmed: 31118632
Mol Ther. 2017 Jan 4;25(1):274-284
pubmed: 28129121
Immunity. 2014 Jul 17;41(1):49-61
pubmed: 25035953
Nanoscale. 2019 Aug 7;11(29):13934-13946
pubmed: 31305839
Biomed Res Int. 2019 May 21;2019:2595801
pubmed: 31240207
Front Oncol. 2020 Jun 09;10:899
pubmed: 32656079
Biotechnol Bioeng. 2016 Jun;113(6):1315-24
pubmed: 26574179
J Extracell Vesicles. 2019 Nov 26;9(1):1696517
pubmed: 31807238
Cancer Lett. 2016 Feb 1;371(1):48-61
pubmed: 26604130
Immunity. 2018 Apr 17;48(4):773-786.e5
pubmed: 29625896
Cell Biol Int. 2017 Feb;41(2):177-186
pubmed: 27987237
Nat Biomed Eng. 2018 Aug;2(8):578-588
pubmed: 31015631
Oncogene. 2017 Oct 26;36(43):6049-6058
pubmed: 28759044
Genome Biol. 2017 Dec 20;18(1):234
pubmed: 29262845
Cancer Lett. 2020 Apr 1;474:36-52
pubmed: 31931030
Hepatology. 2012 Oct;56(4):1342-51
pubmed: 22505239
Front Immunol. 2019 Apr 15;10:792
pubmed: 31037072
Cell Rep. 2019 Aug 20;28(8):2156-2168.e5
pubmed: 31433989
Trends Pharmacol Sci. 2020 Oct;41(10):701-714
pubmed: 32946772
Acta Biomater. 2020 Jan 1;101:519-530
pubmed: 31629893
Theranostics. 2019 Jan 1;9(1):265-278
pubmed: 30662566
PLoS One. 2013 Sep 30;8(9):e76147
pubmed: 24098773
Oncotarget. 2016 Jul 12;7(28):44462-44477
pubmed: 27286448
Sci Transl Med. 2015 Nov 18;7(314):314ra183
pubmed: 26582898
Cancer Res. 2013 Mar 15;73(6):1733-41
pubmed: 23288508
Mol Ther. 2020 Mar 4;28(3):975-985
pubmed: 31911034
Adv Sci (Weinh). 2019 Jun 17;6(16):1900037
pubmed: 31453054
Biosci Rep. 2021 May 28;41(5):
pubmed: 33928349
J Pharm Sci. 2017 Jan;106(1):168-175
pubmed: 27649887
Nat Commun. 2015 Oct 27;6:8692
pubmed: 26503691
J Nanobiotechnology. 2019 Sep 3;17(1):93
pubmed: 31481080
J Am Heart Assoc. 2018 Aug 7;7(15):e008737
pubmed: 30371236
Cancer Immunol Res. 2017 Dec;5(12):1109-1121
pubmed: 29097420
Front Immunol. 2019 May 24;10:1084
pubmed: 31178859
PLoS One. 2017 Jan 12;12(1):e0170042
pubmed: 28081243
Mol Ther. 2021 May 5;29(5):1729-1743
pubmed: 33484965
Oncoimmunology. 2016 Feb 18;5(4):e1118599
pubmed: 27141404
Biomater Res. 2016 Aug 05;20:21
pubmed: 27499886